美国 - 英文 - NLM (National Library of Medicine)

major pharmaceuticals - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

美国 - 英文 - NLM (National Library of Medicine)

st marys medical park pharmacy - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

美国 - 英文 - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see warnings, neutropenia/agranulocytosis ). in considering use of enalapril maleate, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. do not coadminister aliskiren with enalapril maleate in patients with diabetes (see precautions, drug interactions ). enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings, head and neck angioedema ).

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - enalapril (enalapril maleate), hydrochlorothiazide - tablets - 10mg+ 12,5mg

亚美尼亚 - 英文 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - enalapril (enalapril maleate), hydrochlorothiazide - tablets - 10mg+ 25mg

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - enalapril maleate 10mg - tablet - 10 mg - active: enalapril maleate 10mg excipient: hypromellose iron oxide red lactose monohydrate maize starch maleic acid zinc stearate - treatment of renovascular hypertension

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - enalapril maleate 20mg - tablet - 20 mg - active: enalapril maleate 20mg excipient: hypromellose iron oxide red iron oxide yellow lactose monohydrate maize starch maleic acid zinc stearate - treatment of renovascular hypertension

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - enalapril maleate 5mg - tablet - 5 mg - active: enalapril maleate 5mg excipient: hypromellose lactose monohydrate maize starch maleic acid zinc stearate - treatment of renovascular hypertension

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

multichem nz limited - enalapril maleate 10mg;  ;   - tablet - 10 mg - active: enalapril maleate 10mg     excipient: croscarmellose sodium hypromellose lactose monohydrate maleic acid sodium stearyl fumarate - all grades of essential hypertension.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

multichem nz limited - enalapril maleate 20mg;  ;   - tablet - 20 mg - active: enalapril maleate 20mg     excipient: croscarmellose sodium hypromellose lactose monohydrate maleic acid sodium stearyl fumarate - all grades of essential hypertension.